Beskrivning
| Land | Finland |
|---|---|
| Lista | Small Cap Helsinki |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Optomed PlcInside Information25 September 2024 at 20.00, Helsinki
Inside information, profit warning: Optomed decreases its full year outlook
Optomed decreases its full year 2024 outlook. The Company now expects its full year 2024 revenue to decrease from 2023. In the Software Segment, certain key deliveries have been postponed until 2025, and in the Devices Segment, the traditional distributor and OEM sales have been slower than estimated earlier. Optomed estimates that in the US revenue will grow strongly and grow in China compared to 2023. The Q3-2023 comparison period was positively affected by a delivery to Valencia, Spain worth approximately EUR 800,000.
The sales of Optomed Aurora AEYE have started, and the service has received positive feedback from paying customers. However, the Optomed Aurora AEYE recurring revenue service will not have a material effect on the Company's full year 2024 revenue outlook.
The updated outlook for 2024:
"Optomed expects its full year 2024 revenue to decrease from 2023."
Previously outlook (announced 15 February 2024):
"Optomed expects its full year 2024 revenue to grow compared to 2023."
Optomed utilizes seven thresholds in relation to its revenue guidance: in Optomed's outlook, the revenue may "grow/decrease very strongly", "grow/decrease strongly", "grow/decrease" or "stay on the same level". The Company has set fixed internal percentages to reflect each threshold.
Optomed will publish the Interim Report for January-September 2024 on 7 November 2024.
Optomed Plc
Further enquiries
Juho Himberg, CEO, juho.himberg@optomed.com
Optomed in Brief
Optomed is a Finnish medical technology company and a leading manufacturer of handheld fundus cameras and screening software. Optomed combines handheld fundus cameras with software and artificial intelligence with the aim to transform the diagnostic process of various diseases, such as rapidly increasing diabetic retinopathy. Optomed has offices in Finland, the US and China and the company's products are sold via various sales channels in over 60 countries globally
www.optomed.com